DBV Technologies Completes Screening of Subjects for Phase 3 VITESSE Clinical Trial

DBV Technologies announced the completion of subject selection for the Phase 3 VITESSE study, which is evaluating the Viaskin® Peanut patch in peanut-allergic children ages 4 to 7 years.

Dr. Pharis Mohideen, DBV Medical Director, expressed his satisfaction with this milestone reached one month ahead of schedule and thanked the study sites for their dedication. More than 600 children are participating in this study conducted at 86 international sites.

First results are expected in the fourth quarter of 2025. DBV Technologies continues to focus on this development program to meet the needs of children suffering from food allergies.